Treatment of Metastatic Breast Cancer

2014 ◽  
Vol 12 (5S) ◽  
pp. 759-761 ◽  
Author(s):  
William J. Gradishar
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Endocrine Resistance ◽  
Metastatic Breast ◽  
Response To Treatment ◽  
Annual Conference ◽  
Her2 Positive ◽  
Treatment Regimens ◽  
New Strategies

Many newer agents in combination are being studied in the front-line treatment of women with HER2-positive metastatic breast cancer (MBC), but the story in the endocrine arena is more about the wise use of new strategies to overcome endocrine resistance, because no new antihormonal agents have been approved in the past decade. During his presentation at the NCCN 19th Annual Conference, Dr. William Gradishar explored what’s new in the treatment of MBC, focusing primarily on enhancing the effect of endocrine therapy to overcome resistance with newer targeted agents such as everolimus, reevaluating the role of rebiopsy on disease progression and measuring circulating tumor cells as a surrogate of response to treatment, and reviewing the effective treatment regimens for HER2-positive disease.

Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e13018-e13018 ◽  
Author(s):  
Ran Ran ◽  
Wenfa Huang ◽  
Shao Lin ◽  
Yunyun Niu ◽  
Hope S. Rugo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Metastatic Breast ◽  
Gene Copy ◽  
Prognostic Role ◽  
Her2 Gene ◽  
Her2 Positive

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review

Breast Cancer ◽  
2009 ◽  
Vol 16 (4) ◽  
pp. 295-300 ◽  
Author(s):  
Yutaka Tokuda ◽  
Yasuhiro Suzuki ◽  
Yuki Saito ◽  
Shinobu Umemura
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Her2 Positive

scholarly journals Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Massimo Cristofanilli
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Triple Negative ◽  
Treatment Options ◽  
Safety Data ◽  
Metastatic Breast ◽  
Response To Treatment ◽  
Epothilone B ◽  
Metastatic Setting

Successful management of breast cancer in the metastatic setting is often confounded by resistance to chemotherapeutics, in particular anthracyclines and taxanes. The limited number of effective treatment options for patients with more aggressive biological subtypes, such as triple-negative metastatic breast cancer, is especially concerning. As such, a therapy clinically proven to be effective in this subtype would be of great value. Ixabepilone, a novel synthetic lactam analog of epothilone B, demonstrated better clinical outcomes in metastatic disease, particularly in triple-negative breast cancer. Most recently, studies have shown the activity of ixabepilone in the neoadjuvant setting, suggesting a role for this drug in primary disease. Notably, treating in the neoadjuvant setting might allow clinicians to explore the predictive value of biomarkers and response to treatment, as pharmacogenomic approaches to therapy continue to evolve. In this article, we review the efficacy and safety data of ixabepilone as a monotherapy and as a component of combination therapy for metastatic and primary breast cancer.

Sign in / Sign up

Export Citation Format

Share Document